Study identifier:D4300C00016
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-label, Randomized, Four-way Crossover Study in Healthy Male Subjects to Assess the Relative Bioavailability of 4 Different Fostamatinib Tablets
Bioavailability, pharmacokinetics
Phase 1
Yes
Fostamatinib
Male
24
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Fostamatinib 50 mg tablet x 2 | Drug: Fostamatinib Oral tablets, 50 mg x 2, single dose |
Experimental: 2 Fostamatinib 100 mg tablet (batch 1) | Drug: Fostamatinib Oral tablets, 100 mg Batch 1, single dose |
Experimental: 3 Fostamatinib 100 mg tablet (batch 2) | Drug: Fostamatinib Oral tablets, 100 mg Batch 2, single dose |
Experimental: 4 Fostamatinib 100 mg tablet (batch 4) | Drug: Fostamatinib Oral tablets, 100 mg Batch 3, single dose |